Trending...
- Spokane: Council to Hold Press Conference to Discuss Further Information on Department of Justice Grant
- TBM Council Appoints U.S. Department of Transportation CDIO Pavan Pidugu to Board of Directors
- Spokane: Male In Custody After Puppy Is Thrown From Moving Vehicle During Argument; Puppy Located By Neighbor Unharmed
SEATTLE, March 31, 2021 /PRNewswire/ -- OpenTreatments Foundation, a nonprofit organization with a mission to enable treatments for rare genetic diseases regardless of rarity and geography, today announced the launch of OpenTreatments, an innovative open source software platform that will enable patients to create gene therapies for rare genetic diseases. The platform enables patient-led organizations to develop treatments using the Adeno Associated Virus (AAV) gene therapy technology. It provides a robust roadmap, advice from drug development experts, and research infrastructure (labs, contract research facilities, manufacturing facilities, software tools) to execute every step of the drug development pipeline from planning, design, manufacturing, all the way to clinical trials.
"Rare disease drug development is a complex maze. OpenTreatments software platform empowers patient-led organizations to navigate that maze and create treatments for the diseases they care about. We will enable the hand off of these therapies to commercial, governmental and philanthropic entities to ensure patients get access to the therapies for the years to come", said Sanath Kumar Ramesh, founder and CEO of the OpenTreatments Foundation.
The Linux Foundation, a nonprofit organization enabling mass innovation through open source, is collaborating with OpenTreatments Foundation through RareCamp software project to provide open governance and source code for OpenTreatments platform.
More on Washingtoner
There are 400 million patients worldwide affected by more than 7,000 rare diseases, yet treatments for rare genetic diseases are an underserved area. More than 95 percent of rare diseases do not have an approved treatment, and new treatments are estimated to cost more than $1 billion. "Recently, patient groups have risen as the primary driving force behind drug development for rare diseases. The support provided by OpenTreatments to patient-led organizations will dramatically reduce both the time and cost of drug development, leading to more treatments reaching patients faster.", said Dr. Ashley Winslow, Chief Scientific Officer of Odylia Therapeutics, a non-profit organization working to bring treatments to rare diseases and a collaborator of OpenTreatments Foundation.
OpenTreatments Foundation is a collaborative effort with patients, advocacy and industry organizations. Baylor College of Medicine, Castle IRB, Charles River, Columbus Children's Foundation, GlobalGenes, Odylia Therapeutics, RARE-X, and Turing.com are collaborating with OpenTreatments Foundation to support patient-led organizations with drug development advice and research infrastructure necessary to advance their treatments. Amazon Web Services (AWS) is providing expert advice and support to develop and run the OpenTreatments software platform on the AWS cloud. OpenTreatments Foundation's leadership includes patients and rare disease drug development experts Julia Vitarello, Dr. Plavi Mittal, and Dr. Ethan Perlstein as board of directors and Sanath Kumar Ramesh as the Founder and CEO.
More on Washingtoner
OpenTreatments software platform is launching with three pilot gene therapy programs from patient-led organizations CureCMD, IDefine and CureGPX4. "OpenTreatments will enable IDefine to accelerate our mission by distilling down the necessary steps in the development of a gene therapy program into a concise and approachable plan", said Geoff Rhyne, Co-Founder and CEO of IDefine, a patient-led organization tackling Kleefstra Syndrome caused by mutations in EHMT1 gene.
Patient-led organizations with an interest in building gene therapy can apply to join the platform at OpenTreatments.org.
About OpenTreatments Foundation
OpenTreatments Foundation's mission is to enable treatments for all genetic diseases regardless of rarity and geography. Through the OpenTreatments software platform, patient-led organizations get access to a robust roadmap, people, and infrastructure necessary to build a gene therapy program. The software platform offers project management capabilities to manage the program while reducing time and money necessary for the development. For more information, please visit: OpenTreatments.org.
Media Contact
Jennifer Cloer
for the OpenTreatements Foundation
and Linux Foundation
503-867-2304
[email protected]
SOURCE OpenTreatments Foundation
"Rare disease drug development is a complex maze. OpenTreatments software platform empowers patient-led organizations to navigate that maze and create treatments for the diseases they care about. We will enable the hand off of these therapies to commercial, governmental and philanthropic entities to ensure patients get access to the therapies for the years to come", said Sanath Kumar Ramesh, founder and CEO of the OpenTreatments Foundation.
The Linux Foundation, a nonprofit organization enabling mass innovation through open source, is collaborating with OpenTreatments Foundation through RareCamp software project to provide open governance and source code for OpenTreatments platform.
More on Washingtoner
- Robert D. Botticelli Promoted to Century Fasteners Corp. – Director of Sales
- Openchannelflow Wins Web Excellence Award for Outstanding Digital Experience
- STS Capital Partners' Andy Harris Co-Authors 'The Extraordinary Exit,' A Practical Guide for Business Owners Considering a Sale
- One-Click Pro Audio for Streamers: "VoiceSterize" Automates Noise Reduction & Mastering on Mac
- Sole Publishing Announces Essential Parenting Book for Families Navigating the Teen Years
There are 400 million patients worldwide affected by more than 7,000 rare diseases, yet treatments for rare genetic diseases are an underserved area. More than 95 percent of rare diseases do not have an approved treatment, and new treatments are estimated to cost more than $1 billion. "Recently, patient groups have risen as the primary driving force behind drug development for rare diseases. The support provided by OpenTreatments to patient-led organizations will dramatically reduce both the time and cost of drug development, leading to more treatments reaching patients faster.", said Dr. Ashley Winslow, Chief Scientific Officer of Odylia Therapeutics, a non-profit organization working to bring treatments to rare diseases and a collaborator of OpenTreatments Foundation.
OpenTreatments Foundation is a collaborative effort with patients, advocacy and industry organizations. Baylor College of Medicine, Castle IRB, Charles River, Columbus Children's Foundation, GlobalGenes, Odylia Therapeutics, RARE-X, and Turing.com are collaborating with OpenTreatments Foundation to support patient-led organizations with drug development advice and research infrastructure necessary to advance their treatments. Amazon Web Services (AWS) is providing expert advice and support to develop and run the OpenTreatments software platform on the AWS cloud. OpenTreatments Foundation's leadership includes patients and rare disease drug development experts Julia Vitarello, Dr. Plavi Mittal, and Dr. Ethan Perlstein as board of directors and Sanath Kumar Ramesh as the Founder and CEO.
More on Washingtoner
- From Factory Floor to Community Heart: The Rebel Spirit of Wisconsin's Wet Wipe Innovators
- UK Financial Ltd Lists MayaFund (MFUND) ERC-20 Token on CATEX Exchange Ahead of Planned ERC-3643 Upgrade
- Denver Apartment Finders Launches Revamped Denver Tech Center Apartment Location Page
- Roblox and Solsten Alliances; a Stronger Balance Sheet and Accelerated Growth Through AI, Gaming, and Strategic Partnerships for Super League: $SLE
- Boston Industrial Solutions' Natron® 512N Series UV LED Ink Earns CPSIA Certification
OpenTreatments software platform is launching with three pilot gene therapy programs from patient-led organizations CureCMD, IDefine and CureGPX4. "OpenTreatments will enable IDefine to accelerate our mission by distilling down the necessary steps in the development of a gene therapy program into a concise and approachable plan", said Geoff Rhyne, Co-Founder and CEO of IDefine, a patient-led organization tackling Kleefstra Syndrome caused by mutations in EHMT1 gene.
Patient-led organizations with an interest in building gene therapy can apply to join the platform at OpenTreatments.org.
About OpenTreatments Foundation
OpenTreatments Foundation's mission is to enable treatments for all genetic diseases regardless of rarity and geography. Through the OpenTreatments software platform, patient-led organizations get access to a robust roadmap, people, and infrastructure necessary to build a gene therapy program. The software platform offers project management capabilities to manage the program while reducing time and money necessary for the development. For more information, please visit: OpenTreatments.org.
Media Contact
Jennifer Cloer
for the OpenTreatements Foundation
and Linux Foundation
503-867-2304
[email protected]
SOURCE OpenTreatments Foundation
0 Comments
Latest on Washingtoner
- Expert Law Attorneys 2025 Best Attorneys
- Best Family Law Attorneys Of 2025 - ELA Awards
- Best Criminal Defense Attorneys Of 2025 - ELA Awards
- Americans Need $1.26 Million to Retire But Have Just $38K Saved — So They're Building Income Instead
- Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
- New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
- GlobalBoost Media (BSTY) Shows Bullish Signals: Technical Analysis and Exchange Updates
- Spokane: Male In Custody After Puppy Is Thrown From Moving Vehicle During Argument; Puppy Located By Neighbor Unharmed
- $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
- The Brave and the Rescued Honors LA Fire Department First Responders
- Slick Cash Loan shares credit score tips for borrowers using bad credit loans
- Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
- PromptBuilder.cc Launches AI Prompt Generator Optimized For ChatGPT, Gemini, Grok & Claude
- Spokane: Council to Hold Press Conference to Discuss Further Information on Department of Justice Grant
- UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token
- Tacoma: OMWBE Certification 201 Workshop on February 12
- TBM Council Appoints U.S. Department of Transportation CDIO Pavan Pidugu to Board of Directors
- NOW OPEN - New Single Family Home Community in Manalapan
- Kintetsu And Oversee Announce New Partnership
- Save 10 Percent Off KeysCaribbean's Newly Added Luxury Vacation Home in Marathon